Compare
Elicio Therapeutics, Inc. vs BeyondSpring Inc. vs CASI Pharmaceuticals, Inc. vs Integrated Biopharma Inc
| Latest fiscal year | Elicio Therapeutics, Inc. ELTX | BeyondSpring Inc. BYSI | CASI Pharmaceuticals, Inc. CASIF | Integrated Biopharma Inc INBP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-06-30 |
| Revenue | n/a | $0 | $20.71M | $54.35M |
| Revenue growth (YoY) | n/a | n/a | -27.4% | +8.0% |
| Gross margin | n/a | n/a | 48.6% | 10.2% |
| Operating margin | n/a | n/a | -217.3% | 3.7% |
| Net margin | n/a | n/a | -232.0% | 1.5% |
| Net income | -$39.57M | -$1.01M | -$48.06M | $808.0K |
| EPS (Diluted) | -$2.58 | n/a | -$2.59 | $0.03 |
| Operating cash flow | -$36.95M | -$19.77M | -$20.75M | $2.06M |
| Free cash flow | -$36.97M | -$19.82M | -$20.77M | $1.87M |
| Cash & equivalents | $18.56M | $7.79M | $5.63M | $3.62M |
| Total assets | $25.86M | $25.93M | $25.65M | $24.90M |
| Total liabilities | $24.23M | $49.92M | $62.93M | $4.58M |
| Shareholders' equity | $1.64M | -$23.99M | -$37.28M | $20.32M |
| Return on year-end equity | n/m | n/a | n/a | 4.0% |
| Shares outstanding | 17.80M | n/a | 20.56M | 31.06M |
Revenue, most recent five fiscal years
| Fiscal year | Elicio Therapeutics, Inc. | BeyondSpring Inc. | CASI Pharmaceuticals, Inc. | Integrated Biopharma Inc |
|---|---|---|---|---|
| Latest | $2.30M Ended 2022-12-31 | $0 Ended 2025-12-31 | $20.71M Ended 2025-12-31 | $54.35M Ended 2025-06-30 |
| 1 year earlier | $28.31M Ended 2021-12-31 | $0 Ended 2024-12-31 | $28.54M Ended 2024-12-31 | $50.32M Ended 2024-06-30 |
| 2 years earlier | $2.88M Ended 2020-12-31 | $0 Ended 2023-12-31 | $33.88M Ended 2023-12-31 | $50.67M Ended 2023-06-30 |
| 3 years earlier | n/a | $1.35M Ended 2022-12-31 | $43.11M Ended 2022-12-31 | $56.25M Ended 2022-06-30 |
| 4 years earlier | n/a | $1.35M Ended 2021-12-31 | $30.17M Ended 2021-12-31 | $63.56M Ended 2021-06-30 |